Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry. A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back. Here are 10 medtech companies […]
Bio-Rad
Bio-Rad beats The Street in Q4, despite nearly $1.6B loss
Bio-Rad posted fourth-quarter results that beat the overall consensus on Wall Street. The Hercules, California–based clinical diagnostics company yesterday evening reported losses of $1.573 billion, or $52.59 per share, on sales of $732.8 million for the three months ended Dec. 31, 2021. In comparison, the company earned $839.1 million, or $27.81 pers share off sales […]
Bio-Rad appoints Simon May as life sciences group president
Bio-Rad today announced that it appointed Simon May as executive VP and life sciences group president, effective January 4, 2022. May succeeds Annette Tumolo who is retiring. He will be responsible for providing leadership and management of the overall strategy and business direction for the company’s life science group global operations. “We are pleased to […]
How medtech fared in the first waves of the pandemic
Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data. Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial […]
Abbott alleges former employee took COVID-19-related trade secrets
Abbott (NYSE:ABT) has obtained a temporary restraining order against a former marketing executive. The company alleges the former employee stole trade secrets, including details of upcoming COVID-19 products, before accepting a role at a competitor. Virginia Kendall, a U.S. District Judge for the Northern District of Illinois, decided to grant the two-week restraining order against Jerome […]
AdvaMed unveils COVID-19 diagnostic supply registry
AdvaMed announced today that it created a comprehensive national COVID-19 diagnostic supply registry to aid state and federal pandemic responses. According to a news release, AdvaMed is launching the registry in partnership with 13 commercial diagnostics manufacturers: Abbott (NYSE:ABT), Becton Dickinson (NYSE:BDX), bioMérieux, Bio-Rad Laboratories (NYSE:BIO), Beckman Coulter, Cepheid, Hologic (NSDQ:HOLX), Ortho Clinical Diagnostics, Qiagen (NYSE:QGEN), Roche Diagnostics, Sekisui Diagnostics, […]
Bio-Rad acquires Celsee
Bio-Rad Laboratories (NYSE:BIO) this week said it acquired Celsee for an undisclosed amount. Celsee develops instruments and consumables for the isolation, detection and analysis of single cells. The company’s Genesis System allows scientists to isolate, analyze and interpret cellular behavior and collect cell-based information for improved results in single-cell cytometry, single-cell transcriptomics, single-cell multiomics, rare-cell enrichment […]
Bio-Rad launches COVID-19 assay
Bio-Rad Laboratories (NYSE:BIO) today said it is launching is blood-based immunoassay kit to identify COVID-19 antibodies. The assay is currently undergoing clinical evaluation in several hospitals, but 700 samples of data have shown specificity above 99%. After being infected with SARS-CoV-2, viral antigens stimulate the immune system to produce antibodies and fight the virus. Bio-Rad suggests […]
Bio-Rad Laboratories appoints new head of clinical diagnostics group
Research and clinical diagnostics company Bio-Rad Laboratories (NYSE:BIO) announced that it has appointed Dara Grantham Wright as its executive VP and president of the clinical diagnostics group in a move made effective on Jan. 1. Grantham Wright is taking over for John Hertia, who retired from the position on Dec. 31, 2019. Her responsibilities include providing […]
Bio-Rad beats expectations on Q2 results
Bio-Rad Laboratories (NYSE:BIO) posted second-quarter earnings this evening that beat the consensus forecast on Wall Street. The Hercules, Calif.–based life science research and clinical diagnostics manufacturer reported profits of $598.8 million, or $19.86 per share, on sales of $572.6 million for the three months ended June 30, for the bottom-line more than doubling and sales slightly declining compared […]
Bio-Rad shares steady on Street-topping Q1 earnings
Bio-Rad Laboratories (NYSE:BIO) shares are down slightly, but outpacing a general sell-off spurred by fears of a global trade war, after posting first quarter earnings that topped expectations on Wall Street. The Hercules, Calif.-based company posted profits of approximately $865.2 million, or $28.74 per share, on sales of approximately $554 million for the three months […]
